Celldex Therapeutics (CLDX) News Today

Celldex Therapeutics (NASDAQ:CLDX) Shares Up 8.2%

Swiss National Bank grew its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 17.8% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 114,300 shares of the biopharmaceutical

SG Americas Securities LLC lessened its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 56.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,276 shares of the biopharmaceuti

HC Wainwright reaffirmed a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Tuesday.

BNP Paribas Financial Markets reduced its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 59.0% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 56,044 shares of the biopharmaceutical company's s

Jennison Associates LLC raised its stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 3,327.0% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 688,080 shares of the biopharmaceutical company's stock after buying an additional 668,

Vanguard Group Inc. raised its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 16.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,046,331 shares of the biopharmaceutical company's stock after pu

Wellington Management Group LLP boosted its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 19.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 6,476,561 shares of the biop

Celldex Therapeutics (NASDAQ:CLDX) Shares Gap Up to $34.91

Cantor Fitzgerald reiterated an "overweight" rating and set a $67.00 price objective on shares of Celldex Therapeutics in a research note on Tuesday.

Stifel Nicolaus initiated coverage on Celldex Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $58.00 price objective for the company.

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the target of a large drop in short interest in the month of May. As of May 31st, there was short interest totalling 6,270,000 shares, a drop of 5.3% from the May 15th total of 6,620,000 shares. Based on an average daily volume of 691,800 shares, the days-to-cover ratio is presently 9.1 days.

Octagon Capital Advisors LP trimmed its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 6.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 707,526 shares of the

Point72 Asset Management L.P. lifted its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 105.3% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,756,122 shares of the biopharmaceutical company's stock after purchasing an

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) VP Elizabeth Crowley sold 15,000 shares of the company's stock in a transaction on Friday, June 7th. The stock was sold at an average price of $35.06, for a total transaction of $525,900.00. Following the sale, the vice president now directly owns 9,074 shares in the company, valued at $318,134.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Wolfe Research initiated coverage on Celldex Therapeutics in a research note on Tuesday. They set an "outperform" rating and a $51.00 target price for the company.

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the five brokerages that are covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have given a

Bellevue Group AG lifted its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 27.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 2,416,296 shares of the biopharmaceutical company's stock after acquiring an additional 516,296

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Stock analysts at Lifesci Capital issued their Q2 2024 earnings per share (EPS) estimates for shares of Celldex Therapeutics in a research note issued to investors on Friday, June 7th. Lifesci Capital analyst S. Slutsky forecasts that the b

UBS Group AG boosted its position in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 645.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 158,092 shares of the biopharmaceutical company's

Celldex Therapeutics (NASDAQ:CLDX) Trading 4.5% Higher

Affinity Asset Advisors LLC raised its holdings in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 166.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 400,000 shares of the biopharmaceutica

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) CFO Samuel Bates Martin sold 35,000 shares of the firm's stock in a transaction dated Thursday, May 30th. The stock was sold at an average price of $34.05, for a total value of $1,191,750.00. Following the sale, the chief financial officer now directly owns 25,128 shares in the company, valued at approximately $855,608.40. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the recipient of a significant decrease in short interest in May. As of May 15th, there was short interest totalling 6,620,000 shares, a decrease of 5.3% from the April 30th total of 6,990,000 shares. Based on an average trading volume of 896,300 shares, the days-to-cover ratio is presently 7.4 days.

Monashee Investment Management LLC bought a new stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 100,209 shares of the biopharmaceutical company's stock, valued a

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 5.4%

Charles Schwab Investment Management Inc. raised its holdings in Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 13.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 409,391 shares of the biopharmaceutical company's stoc

Assenagon Asset Management S.A. bought a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 90,931 shares of the biopharmaceutical

HC Wainwright reiterated a "buy" rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research report on Wednesday.

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities research analysts at Lifesci Capital issued their FY2024 earnings per share (EPS) estimates for Celldex Therapeutics in a research note issued on Tuesday, May 7th. Lifesci Capital analyst S. Slutsky expects that the biopharmaceutic

HC Wainwright restated a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research report on Tuesday.

HC Wainwright reissued a "buy" rating and set a $80.00 price objective on shares of Celldex Therapeutics in a research note on Wednesday.